Literature DB >> 19357536

The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round.

Jesper H Pedersen1, Haseem Ashraf, Asger Dirksen, Karen Bach, Hanne Hansen, Phillip Toennesen, Hanne Thorsen, John Brodersen, Birgit Guldhammer Skov, Martin Døssing, Jann Mortensen, Klaus Richter, Paul Clementsen, Niels Seersholm.   

Abstract

INTRODUCTION: Lung cancer screening with low dose computed tomography (CT) has not yet been evaluated in randomized clinical trials, although several are underway.
METHODS: In The Danish Lung Cancer Screening Trial, 4104 smokers and previous smokers from 2004 to 2006 were randomized to either screening with annual low dose CT scans for 5 years or no screening. A history of cigarette smoking of at least 20 pack years was required. All participants have annual lung function tests, and questionnaires regarding health status, psychosocial consequences of screening, smoking habits, and smoking cessation. Baseline CT scans were performed in 2052 participants. Pulmonary nodules were classified according to size and morphology: (1) Nodules smaller than 5 mm and calcified (benign) nodules were tabulated, (2) Noncalcified nodules between 5 and 15 mm were rescanned after 3 months. If the nodule increased in size or was larger than 15 mm the participant was referred for diagnostic workup.
RESULTS: At baseline 179 persons showed noncalcified nodules larger than 5 mm, and most were rescanned after 3 months: The rate of false-positive diagnoses was 7.9%, and 17 individuals (0.8%) turned out to have lung cancer. Ten of these had stage I disease. Eleven of 17 lung cancers at baseline were treated surgically, eight of these by video assisted thoracic surgery resection.
CONCLUSIONS: Screening may facilitate minimal invasive treatment and can be performed with a relatively low rate of false-positive screen results compared with previous studies on lung cancer screening.

Entities:  

Mesh:

Year:  2009        PMID: 19357536     DOI: 10.1097/JTO.0b013e3181a0d98f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  95 in total

1.  Identification of low-frequency variants associated with gout and serum uric acid levels.

Authors:  Patrick Sulem; Daniel F Gudbjartsson; G Bragi Walters; Hafdis T Helgadottir; Agnar Helgason; Sigurjon A Gudjonsson; Carlo Zanon; Soren Besenbacher; Gyda Bjornsdottir; Olafur T Magnusson; Gisli Magnusson; Eirikur Hjartarson; Jona Saemundsdottir; Arnaldur Gylfason; Adalbjorg Jonasdottir; Hilma Holm; Ari Karason; Thorunn Rafnar; Hreinn Stefansson; Ole A Andreassen; Jesper H Pedersen; Allan I Pack; Marieke C H de Visser; Lambertus A Kiemeney; Arni J Geirsson; Gudmundur I Eyjolfsson; Isleifur Olafsson; Augustine Kong; Gisli Masson; Helgi Jonsson; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-09       Impact factor: 38.330

Review 2.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

3.  National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.

Authors:  Edward F Patz; Neil E Caporaso; Steven M Dubinett; Pierre P Massion; Fred R Hirsch; John D Minna; Constantine Gatsonis; Fenghai Duan; Amanda Adams; Charles Apgar; Rosa M Medina; Denise R Aberle
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

4.  Lung cancer screening: current status.

Authors:  Theresa C McLoud
Journal:  Radiol Med       Date:  2013-11-22       Impact factor: 3.469

Review 5.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 6.  European and North American lung cancer screening experience and implications for pulmonary nodule management.

Authors:  Arjun Nair; David M Hansell
Journal:  Eur Radiol       Date:  2011-08-10       Impact factor: 5.315

Review 7.  Implementing lung cancer screening in the real world: opportunity, challenges and solutions.

Authors:  Robert J Optican; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2015-08

8.  Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial.

Authors:  Mathilde M Winkler Wille; Sarah J van Riel; Zaigham Saghir; Asger Dirksen; Jesper Holst Pedersen; Colin Jacobs; Laura Hohwü Thomsen; Ernst Th Scholten; Lene T Skovgaard; Bram van Ginneken
Journal:  Eur Radiol       Date:  2015-03-13       Impact factor: 5.315

9.  Lung nodule volumetry: segmentation algorithms within the same software package cannot be used interchangeably.

Authors:  H Ashraf; B de Hoop; S B Shaker; A Dirksen; K S Bach; H Hansen; M Prokop; J H Pedersen
Journal:  Eur Radiol       Date:  2010-03-20       Impact factor: 5.315

Review 10.  Lung cancer screening.

Authors:  U Pastorino
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.